TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
←
▶ 22:00 · $ALTOS-LABS · Nobel laureate skeptical of Altos Labs' reprogramming approach for human longevity
episode briefing
In Good Company with Nicolai Tangen

Venki Ramakrishnan: The Science and Hype of Living Longer | Podcast | In Good Company

2026-07-22 · 2 company · 4 thematic
sentiment
0 bull1 bear1 neu
speakers
venki ramakrishnan

Venki Ramakrishnan shared the 2009 Nobel Prize in Chemistry for ribosome structure work, served as President of the Royal Society (2015-2020), and authored 'Why We Die: The New Science of Aging and the Quest for Immortality'.

quote
“I think they're their bet is if we hire some top scientists they will come up with useful stuff that then we can monetize in the longevity business. And so that's a clear, you know, standard, you know, investment strategy. But the other st…”
—venki ramakrishnan
now playing · $ALTOS-LABS
$ISOMORPHIC-LABSbearish· mediumvenki ramakrishnan
Demis Hassabis's Isomorphic Labs overoptimistic on AI eliminating all disease in 10-15 years
While AlphaFold revolutionized protein structure prediction, translating AI insights into actual treatments requires navigating the analog world of clinical trials, manufacturing,…
$ALTOS-LABSneutral· lowvenki ramakrishnan
Nobel laureate skeptical of Altos Labs' reprogramming approach for human longevity
Altos Labs has hired top scientists with massive funding ($5B) to pursue cellular reprogramming, but the approach faces major hurdles: heterogeneous reprogramming in tissues, onco…